Submitted:
17 August 2023
Posted:
21 August 2023
You are already at the latest version
Abstract

Keywords:
1. Introduction
2. Results
2.1. Nonheritable persistence of Mtb in alveolar macrophages is the main culprit of treatment failure in TB patients
2.1.1. Mtb-infected alveolar macrophages are determined for all the patients after an intensive anti-TB chemotherapy
2.1.2. Mtb are genetically susceptible to the many antibiotics used in clinical settings
2.1.3. Mtb survive in alveolar macrophages after exposure to bactericidal antibiotics in a long-term ex vivo culture
2.2. Mtb resume active growth in the alveolar macrophages of some patients in the prolonged ex vivo cell cultures after withdrawal of anti-TB drugs
2.3. Acid-fast and LAM-positive Mtb with an atypical morphology appear in the alveolar macrophages of some patients in a long-term ex vivo culture under antibiotic-free conditions
2.4. Mtb within and outside alveolar macrophages of TB patients are devoid of lipophilic inclusions
2.5. Rv2623-positive Mtb are detected only in stationary phase cultures, but not in exponential phase cultures of Mtb Beijing clinical isolates
2.6. Rv2623-positive Mtb not expressing the virulence factors LAM and ESAT-6 are identified in the alveolar macrophages of all the patients studied
2.7. Rv2623-positive Mtb are acid-fast-negative in the alveolar macrophages of patients and guinea pig with TB disease
2.8. Subpopulations of phenotypically and physiologically distinct Mtb coexist in the same lung tissues of TB patients, no matter what lesion type
3. Discussion
4. Materials and Methods
4.1. Patients and lung tissue samples
4.2. Analysis of drug-resistance mutations in Mtb genes
4.3. Bacterial strains and cultures
4.4. Ex vivo isolation and culture of human cells
4.5. Guinea pig infection and ex vivo isolation of animal cells
4.6. Cell staining
4.7. Histology
4.8. Microscopy
4.9. Statistical analyses
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- World Health Organization. In Global tuberculosis report; 2022.
- World Health Organization. Drug-resistant TB: Surveillance and response. Supplement to Global tuberculosis report 2014; WHO: Geneva, Switzerland, 2014. [Google Scholar]
- Beltran, C.G.G.; Heunis, T.; Gallant, J.; Venter, R.; du Plessis, N.; Loxton, A.G.; Trost, M.; Winter, J.; Malherbe, S.T.; Kana, B.D.; et al. Investigating non-sterilizing cure in TB patients at the end of successful anti-TB therapy. Front. Cell. Infect. Microbiol. 2020, 10, 443. [Google Scholar] [CrossRef] [PubMed]
- Müller, B.; Borrell, S.; Rose, G.; Gagneux, S. The heterogeneous evolution of multidrug-resistant Mycobacterium tuberculosis. Trends in Genetics 2013, 29, 160–167. [Google Scholar] [CrossRef] [PubMed]
- Olaru, I.D.; Lange, C.; Heyckendorf, J. Personalized medicine for patients with MDR-TB. J. Antimicrob. Chemother. 2016, 71, 852–855. [Google Scholar] [CrossRef] [PubMed]
- Prozorov, A.A.; Zaichikova, M.V.; Danilenko, V.N. Mycobacterium tuberculosis mutants with multidrug resistance: History of origin, genetic and molecular mechanisms of resistance, and emerging challenges. Russ. J. Genet. 2012, 48, 1–14. [Google Scholar] [CrossRef]
- Koch, A.; Cox, H.; Mizrahi, V. Drug-resistant tuberculosis: Challenges and opportunities for diagnosis and treatment. Curr. Opin. Pharmacol. 2018, 42, 7–15. [Google Scholar] [CrossRef]
- Schrader, S.M.; Vaubourgeix, J.; Nathan, C. Biology of antimicrobial resistance and approaches to combat it. Sci. Transl. Med. 2020, 12, 549. [Google Scholar] [CrossRef]
- Sterwart, G.R.; Robertson, B.D.; Young, D.B. Tuberculosis: A problem with persistence. Nat. Rev. Microbiol. 2003, 1, 97–105. [Google Scholar] [CrossRef]
- Connolly, L.E.; Edelstein, P.H.; Ramakrishnan, L. Why is long-term therapy required to cure tuberculosis? PLoS Med. 2007, 4, e120. [Google Scholar] [CrossRef]
- Antonova, A.V.; Gryadunov, D.A.; Zimenkov, D.V. Molecular mechanisms of drug tolerance in Mycobacterium tuberculosis. Mol. Biol. 2018, 52, 372–384. [Google Scholar] [CrossRef]
- Boldrin, F.; Provvedi, R.; Mazzabo, L.C.; Segafreddo, G.; Manganelli, R. Tolerance and persistence to drugs: A main challenge in the fight against Mycobacterium tuberculosis. Front. Microbiol. 2020, 11, 1924. [Google Scholar] [CrossRef]
- Helaine, S.; Kugelberg, E. Bacterial persisters: Formation, eradication, and experimental systems. Trends Microbiol. 2014, 22, 417–424. [Google Scholar] [CrossRef] [PubMed]
- Van den Bergh, B.; Fauvart, M.; Michiels, J. Formation, physiology, ecology, evolution and clinical importance of bacterial persisters. FEMS Microbiol. Rev. 2017, 41, 219–251. [Google Scholar] [CrossRef] [PubMed]
- Moldoveanu, A.L.; Rycroft, J.A.; Helaine, S. Impact of bacterial persisters on their host. Curr. Opin. Microbiol. 2021, 59, 1–7. [Google Scholar] [CrossRef]
- Nathan, C.; Barry III, C.E. TB drug development: Immunology at the table. Immunol. Rev. 2015, 264, 308–318. [Google Scholar] [CrossRef] [PubMed]
- Gold, B.; Nathan, C. Targeting phenotypically tolerant Mycobacterium tuberculosis. Microbiol. Spectrum 2017, 5, 5–11. [Google Scholar] [CrossRef] [PubMed]
- Mandal, S.; Njikan, S.; Kumar, A.; Early, J.V.; Parish, T. The relevance of persisters in tuberculosis drug discovery. Microbiology 2019, 165, 492–499. [Google Scholar] [CrossRef]
- Dartois, V.; Rubin, E.J. Anti-tuberculosis treatment strategies and drug development: Challenges and priorities. Nat. Rev. Microbiol. 2022, 20, 685–701. [Google Scholar] [CrossRef]
- Du, P.; Sohaskey, C.D.; Shi, L. Transcriptional and physiological changes during Mycobacterium tuberculosis reactivation from non-replicating persistence. Front. Microbiol. 2016, 7, 1346. [Google Scholar] [CrossRef]
- Hartman, T.E.; Wang, Z.; Jansen, R.S.; Gardete, S.; Rhee, K.Y. Metabolic perspectives on persistence. Microbiol. Spectrum 2017, 5, 5–11. [Google Scholar] [CrossRef]
- Ehrt, S.; Schnappinger, D.; Rhee, K.Y. Metabolic principles of persistence and pathogenicity in Mycobacterium tuberculosis. Nat. Rev. Microbiol. 2018, 16, 496–507. [Google Scholar] [CrossRef]
- Chao, M.C.; Rubin, E.J. Letting sleeping dos lie: Does dormancy play a role in tuberculosis? Annu. Rev. Microbiol. 2010, 64, 293–311. [Google Scholar] [CrossRef] [PubMed]
- Gengenbacher, M.; Kaufmann, S.H.E. Mycobacterium tuberculosis: Success through dormancy. FEMS Microbiol. Rev. 2012, 36, 514–532. [Google Scholar] [CrossRef] [PubMed]
- Lipworth, S.; Hammond, R.J.H.; Baron, V.O.; Hu, Y.; Coates, A.; Gillespie, S.H. Defining dormancy in mycobacterial disease. Tuberculosis 2016, 99, 131–142. [Google Scholar] [CrossRef] [PubMed]
- Campaniço, A.; Harjivan, S.G.; Warner, D.F.; Moreira, R.; Lopes, F. Addressing latent tuberculosis: New advances in mimicking the disease, discovering key targets, and designing hit compounds. Int. J. Mol. Sci. 2020, 21, 8854. [Google Scholar] [CrossRef] [PubMed]
- Wayne, L.G.; Sohaskey, C.D. Nonreplicating persistence of Mycobacterium tuberculosis. Annu. Rev. Microbiol. 2001, 55, 139–163. [Google Scholar] [CrossRef] [PubMed]
- Joshi, H.; Kandari, D.; Bhatnagar, R. Insights into the molecular determinants involved in Mycobacterium tuberculosis persistence and their therapeutic implications. Virulence 2021, 12, 2721–2749. [Google Scholar] [CrossRef]
- Goossens, S.N.; Sampson, S.L.; Van Rie, A. Mechanisms of drug-induced tolerance in Mycobacterium tuberculosis. Clin. Microbiol. Rev. 2021, 34, 1–21. [Google Scholar] [CrossRef]
- Lake, M.A.; Adams, K.N.; Nie, F.; Fowler, E.; Verma, A.K.; Dei, S.; Teodori, E.; Sherman, D.R.; Edelstein, P.H.; Spring, D.R.; et al. The human proton pump inhibitors inhibit Mycobacterium tuberculosis rifampicin efflux and macrophage-induced rifampicin tolerance. Proc. Natl. Acad. Sci. USA 2023, 120, e2215512120. [Google Scholar] [CrossRef]
- Torrelles, J.B.; Schlesinger, L.S. Integrating lung physiology, immunology and tuberculosis. Trends Microbiol. 2017, 25, 688–697. [Google Scholar] [CrossRef]
- Park, H.-E.; Lee, W.; Shin, M.-K.; Shin, S.J. Understanding the reciprocal interplay between antibiotics and host immune system: How can we improve the anti-mycobacterial activity of current drugs to better control tuberculosis? Front. Immunol. 2021, 12, 703060. [Google Scholar] [CrossRef]
- Ufimtseva, E.; Eremeeva, N.; Petrunina, E.; Umpeleva, T.; Karskanova, S.; Baiborodin, S.; Vakhrusheva, D.; Skornyakov, S. Ex vivo expansion of alveolar macrophages with Mycobacterium tuberculosis from the resected lungs of patients with pulmonary tuberculosis. PLoS ONE 2018, 13, e0191918. [Google Scholar] [CrossRef] [PubMed]
- Ufimtseva, E.G.; Eremeeva, N.I.; Petrunina, E.M.; Umpeleva, T.V.; Baiborodin, S.I.; Vakhrusheva, D.V.; Skornyakov, S.N. Mycobacterium tuberculosis cording in alveolar macrophages of patients with pulmonary tuberculosis is likely associated with increased mycobacterial virulence. Tuberculosis 2018, 112, 1–10. [Google Scholar] [CrossRef] [PubMed]
- Ufimtseva, E.; Eremeeva, N.; Baiborodin, S.; Umpeleva, T.; Vakhrusheva, D.; Skornyakov, S. Mycobacterium tuberculosis with different virulence reside within intact phagosomes and inhibit phagolysosomal biogenesis in alveolar macrophages of patients with pulmonary tuberculosis. Tuberculosis 2019, 114, 77–90. [Google Scholar] [CrossRef] [PubMed]
- Ufimtseva, E.; Eremeeva, N.; Bayborodin, S.; Umpeleva, T.; Vakhrusheva, T.; Skornyakov, S. Analysis of Mycobacterium tuberculosis uptake by alveolar macrophages after ex vivo expansion indicates processing host cells with pathogen actually from lung tissue of patients with pulmonary tuberculosis. Int. J. Mycobacteriol. 2020, 9, 176–184. [Google Scholar] [CrossRef] [PubMed]
- Ufimtseva, E.G.; Eremeeva, N.I.; Umpeleva, T.V.; Vakhrusheva, D.V.; Skornyakov, S.N. Mycobacterium tuberculosis load in host cells and the antibacterial activity of alveolar macrophages are linked and differentially regulated in various lung lesions of patients with pulmonary tuberculosis. Int. J. Mol. Sci. 2021, 22, 3452. [Google Scholar] [CrossRef]
- Castro, R.A.D.; Borrell, S.; Gagneux, S. The within-host evolution of antimicrobial resistance in Mycobacterium tuberculosis. FEMS Microbiol. Rev. 2021, 45, fuaa071. [Google Scholar] [CrossRef]
- Ordonez, A.A.; Wang, H.; Magombedze, G.; Ruiz-Bedoya, C.A.; Srivastava, S.; Chen, A.; Tucker, E.W.; Urbanowski, M.E.; Pieterse, L.; Cardozo, E.F.; et al. Dynamic imaging in patients with tuberculosis reveals heterogeneous drug exposures in pulmonary lesions. Nature Med. 2020, 26, 529–534. [Google Scholar] [CrossRef] [PubMed]
- Marimani, M.; Ahmad, A.; Duse, A. The role of epigenetics, bacterial and host factors in progression of Mycobacterium tuberculosis infection. Tuberculosis 2018, 113, 200–214. [Google Scholar] [CrossRef]
- Phthisiology. National guidelines; (In Russian). Perelman, M.I., Ed.; GEOTAR-Media: Moscow, Russia, 2007; ISBN 978-5-9704-0497-3. [Google Scholar]
- Dahl, J.L. Electron microscopy analysis of Mycobacterium tuberculosis cell division. FEMS Microbiol. Lett. 2004, 240, 15–20. [Google Scholar] [CrossRef]
- Thanky, N.R.; Young, D.B.; Robertson, B.D. Unusual features of the cell cycle in mycobacteria: Polar-restricted growth and the snapping-model of cell division. Tuberculosis 2007, 87, 231–236. [Google Scholar] [CrossRef]
- Garton, N.J.; Christensen, H.; Minnikin, D.E.; Adegbola, R.A.; Barer, M.R. Intracellular lipophilic inclusions of mycobacteria in vitro and in sputum. Microbiology 2002, 148, 2951–2958. [Google Scholar] [CrossRef] [PubMed]
- Garton, N.J.; Waddell, S.J.; Sherratt, A.L.; Lee, S.-M.; Smith, R.J.; Senner, C.; Hinds, J.; Rajakumar, K.; Adegbola, R.A.; Besra, G.S.; et al. Cytological and transcript analyses reveal fat and lazy persister-like bacilli in tuberculous sputum. PLoS Med. 2008, 5, e75. [Google Scholar] [CrossRef] [PubMed]
- Mekonnen, D.; Derbie, A.; Mihret, A.; Yimer, S.A.; Tønjum, T.; Gelaw, B.; Nibret, E.; Munshae, A.; Waddell, S.J.; Aseffa, A. Lipid droplets and the transcriptome of Mycobacterium tuberculosis from direct sputa: A literature review. Lipids Health Dis. 2021, 20, 129. [Google Scholar] [CrossRef] [PubMed]
- Boon, C.; Dick, T. How Mycobacterium tuberculosis goes to sleep: The dormancy survival regulator DosR a decade later. Future Microbiol. 2012, 7, 513–518. [Google Scholar] [CrossRef] [PubMed]
- Reed, M.B.; Gagneux, S.; DeRiemer, K.; Small, P.M.; Barry III, C.E. The W-Beijing lineage of Mycobacterium tuberculosis overproduces triglycerides and has the DosR dormancy regulon constitutively upregulated. J. Bacteriol. 2007, 189, 2583–2589. [Google Scholar] [CrossRef]
- Park, H.-D.; Guinn, K.M.; Harrell, M.I.; Liao, R.; Voskuil, M.I.; Tompa, M.; Schoolnik, G.K.; Sherman, D.R. Rv3133c/dosR is a transcription factor that mediates the hypoxic response of Mycobacterium tuberculosis. Mol. Microbiol. 2003, 48, 833–843. [Google Scholar] [CrossRef]
- Karakousis, P.C.; Yoshimatsu, T.; Lamichhane, G.; Woolwine, S.C.; Nuermberger, E.L.; Grosset, J.; Bishai, W.R. Dormancy phenotype displayed by extracellular Mycobacterium tuberculosis within artificial granulomas in mice. J. Exp. Med. 2004, 200, 645–657. [Google Scholar] [CrossRef]
- Monahan, I.M.; Betts, J.; Banerjee, D.K.; Butcher, P.D. Differential expression of mycobacterial proteins following phagocytosis by macrophages. Microbiology 2001, 147, 459–471. [Google Scholar] [CrossRef]
- Shi, L.; Jung, Y.J.; Tyagi, S.; Gennaro, M.L.; North, R.J. Expression of Th1-mediated immunity in mouse lungs induces a Mycobacterium tuberculosis transcription pattern characteristic of nonreplicating persistence. Proc. Natl. Acad. Sci. USA 2003, 100, 241–246. [Google Scholar] [CrossRef]
- Drumm, J.E.; Mi, K.; Bilder, P.; Sun, M.; Lim, J.; Bielefeldt-Ohmann, H.; Basaraba, R.; So, M.; Zhu, G.; Tufariello, J.M.; et al. Mycobacterium tuberculosis universal stress protein Rv2623 regulates bacillary growth by ATP-binding: Requirement for establishing chronic persistent infection. PLoS Pathog. 2009, 5, e1000460. [Google Scholar] [CrossRef]
- Glass, L.N.; Swapna, G.; Chavadi, S.S.; Tufariello, J.M.; Mi, K.; Drumm, J.E.; Lam, T.T.; Zhu, G.; Zhan, C.; Vilchéze, C.; et al. Mycobacterium tuberculosis universal stress protein Rv2623 interacts with the putative ATP binding cassette (ABC) transporter Rv1747 to regulate mycobacterial growth. PLoS Pathog. 2017, 13, e1006515. [Google Scholar] [CrossRef]
- Fukuda, T.; Matsumura, T.; Ato, M.; Hamasaki, M.; Nishiuchi, Y.; Murakami, Y.; Maeda, Y.; Yoshimori, T.; Matsumoto, S.; Kobayashi, K.; et al. Critical roles for lipomannan and lipoarabinomannan in cell wall integrity of mycobacteria and pathogenesis of tuberculosis. mBio 2013, 4, e00472-12. [Google Scholar] [CrossRef]
- Guerin, M.E.; Korduláková, J.; Alzari, P.M.; Brennan, P.J.; Jackson, M. Molecular basis of phosphatidylmyo-inositol mannoside biosynthesis and regulation in mycobacteria. J. Biol. Chem. 2010, 285, 33577–33583. [Google Scholar] [CrossRef]
- Vilchèze, C.; Kremer, L. Acid-fast positive and acid-fast negative Mycobacterium tuberculosis: The Koch paradox. Microbiol. Spectrum 2017, 5, TBTB2-0003. [Google Scholar] [CrossRef] [PubMed]
- Stokas, H.; Rhodes, H.L.; Purdy, G.E. Modulation of the M. tuberculosis cell envelope between replicating and non-replicating persistent bacteria. Tuberculosis 2020, 125, 102007. [Google Scholar] [CrossRef] [PubMed]
- Allué-Guardia, A.; García, J.I.; Torrelles, J.B. Evolution of drug-resistant Mycobacterium tuberculosis strains and their adaptation to the human lung environment. Front. Microbiol. 2021, 12, 612675. [Google Scholar] [CrossRef] [PubMed]
- Seiler, P.; Ulrichs, T.; Bandermann, S.; Pradl, L.; Jörg, S.; Krenn, V.; Morawietz, L.; Kaufmann, S.H.E.; Aichele, P. Cell-wall alterations as an attribute of Mycobacterium tuberculosis in latent infection. J. Infect. Dis. 2003, 188, 1326–1331. [Google Scholar] [CrossRef] [PubMed]
- Ulrichs, T.; Lefmann, M.; Reich, M.; Morawietz, L.; Roth, A.; Brinkmann, V.; Kosmiadi, G.A.; Seiler, P.; Aichele, P.; Hahn, H.; et al. Modified immunohistological staining allows detection of Ziehl–Neelsen-negative Mycobacterium tuberculosis organisms and their precise localization in human tissue. J. Pathol. 2005, 205, 633–640. [Google Scholar] [CrossRef]
- Ufimtseva, E. Differences between Mycobacterium-host cell relationships in latent tuberculous infection of mice ex vivo and mycobacterial infection of mouse cells in vitro. J. Immun. Res. 2016, 2016, 4325646. [Google Scholar] [CrossRef]
- McCune, R.M.; Feldmann, F.M.; Lambert, H.P.; McDermott, W. Microbial persistence. I. The capacity of tubercle bacilli to survive sterilization in mouse tissues. J. Exp. Med. 1966, 123, 445–468. [Google Scholar] [CrossRef]
- McCune, R.M.; Feldmann, F.M.; McDermott, W. Microbial persistence. II. Characteristics of the sterile state of tubercle bacilli. J. Exp. Med. 1966, 123, 469–486. [Google Scholar] [CrossRef]
- de Wit, D.; Wootton, M.; Dhillon, J.; Mitchison, D.A. The bacterial DNA content of mouse organs in the Cornell model of dormant tuberculosis. Tuber. Lung Dis. 1995, 76, 555–562. [Google Scholar] [CrossRef]
- Shleeva, M.O.; Bagramyan, K.; Telkov, M.V.; Mukamolova, G.V.; Young, M.; Kell, D.B.; Kaprelyants, A.S. Formation and resuscitation of ‘nonculturable’ cells of Rhodococcus rhodochrous and Mycobacterium tuberculosis in prolonged stationary phase. Microbiology 2002, 148, 1581–1591. [Google Scholar] [CrossRef]
- Shleeva, M.O.; Kudykina, Y.K.; Vostroknutova, G.N.; Suzina, N.E.; Mulyukin, A.L.; Kaprelyants, A.S. Dormant ovoid cells of Mycobacterium tuberculosis are formed in response to gradual external acidification. Tuberculosis 2011, 91, 146–154. [Google Scholar] [CrossRef] [PubMed]
- Veatch, A.V.; Kaushal, D. Opening Pandora’s box: Mechanisms of Mycobacterium tuberculosis resuscitation. Trends Microbiol. 2018, 26, 145–157. [Google Scholar] [CrossRef] [PubMed]
- Salina, E.G.; Makarov, V. Mycobacterium tuberculosis dormancy: How to fight a hidden danger. Microorganisms 2022, 10, 2334. [Google Scholar] [CrossRef] [PubMed]
- Mukamolova, G.V.; Turapov, O.; Malkin, J.; Woltmann, G.; Barer, M.R. Resuscitation-promoting factors reveal an occult population of tubercle bacilli in sputum. Am. J. Respir. Crit. Care Med. 2010, 181, 174–180. [Google Scholar] [CrossRef] [PubMed]
- Jain, R.K.; Nayak, A.R.; Husain, A.A.; Panchbhai, M.S.; Chandak, N.; Purohit, H.J.; Taori, G.M.; Daginawala, H.F.; Kashyap, R.S. Mycobacterial dormancy regulon protein Rv2623 as a novel biomarker for the diagnosis of latent and active tuberculous meningitis. Dis. Markers 2013, 35, 311–316. [Google Scholar] [CrossRef] [PubMed]
- Dulberger, C.L.; Rubin, E.J.; Boutte, C.C. The mycobacterial cell envelope — a moving target. Nat. Rev. Microbiol. 2020, 18, 47–59. [Google Scholar] [CrossRef]
- Velayati, A.A.; Farnia, P. Morphological characterization of Mycobacterium tuberculosis. In Understanding tuberculosis - deciphering the secret life of the bacilli; Cardona, P.-J., Ed.; InTech: Vienna, Austria, 2012; pp. 149–166. [Google Scholar]
- Jakkala, K.; Ajitkumar, P. Hypoxic non-replicating persistent Mycobacterium tuberculosis develops thickened outer layer that helps in restricting rifampicin entry. Front. Microbiol. 2019, 10, 2339. [Google Scholar] [CrossRef]
- Khomenko, A.G. The variability of Mycobacterium tuberculosis in patients with cavitary pulmonary tuberculosis in the course of chemotherapy. Tubercle 1987, 68, 243–253. [Google Scholar] [CrossRef] [PubMed]
- Dhiman, R.K.; Dinadayala, P.; Ryan, G.J.; Lenaerts, A.J.; Schenkel, A.R.; Crick, D.C. Lipoarabinomannan localization and abundance during growth of Mycobacterium smegmatis. J. Bacteriol. 2011, 193, 5802–5809. [Google Scholar] [CrossRef] [PubMed]
- Rahlwes, K.C.; Osman, S.H.; Morita, Y.S. Role of LmeA, a mycobacterial periplasmic protein, in maintaining the mannosyltransferase MptA and its product lipomannan under stress. mSphere 2020, 5, e01039-20. [Google Scholar] [CrossRef] [PubMed]
- Yiling, G.; Shuliang, G. Controlling strategy of dormant Mycobacterium tuberculosis. Chin. Med. J. 2014, 127, 3316–3321. [Google Scholar] [CrossRef]
- Ufimtseva, E.G.; Eremeeva, N.I. Mesenchymal stem cells in different lung lesions from patients with pulmonary tuberculosis. Genes & Cells 2022, 27, 237–238. (In Russian) [Google Scholar]
- Jain, N.; Kalam, H.; Singh, L.; Sharma, V.; Kedia, S.; Das, P.; Ahuja, V.; Kumar, D. Mesenchymal stem cells offer a drug-tolerant and immune-privileged niche to Mycobacterium tuberculosis. Nat. Commun. 2020, 11, 3062. [Google Scholar] [CrossRef]
- Bhatt, A.; Fujiwara, N.; Bhatt, K.; Gurcha, S.S.; Kremer, L.; Chen, B.; Chan, J.; Porcelli, S.A.; Kobayashi, K.; Besra, G.S.; et al. Deletion of kasB in Mycobacterium tuberculosis causes loss of acid-fastness and subclinical latent tuberculosis in immunocompetent mice. Proc. Natl. Acad. Sci. USA 2007, 104, 5157–5162. [Google Scholar] [CrossRef]
- Vilchèze, C.; Molle, V.; Carrère-Kremer, S.; Leiba, J.; Mourey, L.; Shenai, S.; Baronian, G.; Tufariello, J.; Hartman, T.; Veyron-Churlet, R.; et al. Phosphorylation of KasB regulates virulence and acid-fastness in Mycobacterium tuberculosis. PLoS Pathog. 2014, 10, e1004115. [Google Scholar] [CrossRef]






| Patients | Mutations in the Mtb genes associated with drug resistance to | Diagnosis | Treatment1 | Virulence2 | Mtb isolate3 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| H | R | E | Fq | AK | Drugs | Mo nths | ||||||
| katG | inhA | rpoB | embB | gyrA | rrs | eis | ||||||
| 1 | S315T1 | wt | S531L | wt | wt | wt | wt | MDR TB | Z Pt Cap Pas Cs Of | 24 | n.d. | - |
| 2 | S315T1 | wt | wt | wt | wt | wt | wt | TB | H R Z Pt Cap | 9 | n.d. | - |
| 3 | S315T1 | wt | S531L | wt | wt | wt | wt | MDR TB | H Z Pt Cap Pas Cs | 9 | n.d. | - |
| 4 | wt | wt | wt | wt | wt | wt | wt | TB | H R Z E | 5 | n.d. | - |
| 5 | S315T1 | wt | S531L | wt | wt | wt | wt | MDR TB | H R Z E Pt Cap Cs | 11 | L | - |
| 6 | S315T1 | wt | S531L | wt | wt | a1401g | wt | MDR TB | Z E Pt Cap Сs | 155 | H | + |
| 7 | S315T1 | wt | S531L | M306I | wt | wt | wt | MDR TB | H Z E Pt Cap Cs | 5 | n.d. | - |
| 8 | S315T1 | wt | wt | wt | wt | wt | wt | TB | H Z E Pt Rfd | 5 | H | + |
| 9 | S315T1 | wt | S531L | wt | wt | g1484t | wt | MDR TB | Z Rfd Cap Pas Cs | 31 | n.d. | - |
| 10 | S315T1 | wt | S531L | M306V | D94G | a1401g | wt | XDR TB | Z E Pt Cap Pas Cs | 41 | H | + |
| 11 | S315T1 | wt | S531L | wt | wt | wt | wt | MDR TB | Z Pt Cap Pas Cs | 74 | L | + |
| 12 | S315T1 | wt | S531L | wt | wt | wt | wt | MDR TB | Z Pt Cap Pas Cs | 19 | L | - |
| 13 | wt | wt | wt | wt | wt | wt | wt | TB | H R Z Pt Pas | 3 | L | - |
| 14 | S315T1 | wt | wt | wt | wt | wt | wt | TB | R Z E Pas | 6 | L | - |
| 15 | S315T1 | wt | S531L | M306V | wt | wt | wt | MDR TB | H R Z E | 58 | L | - |
| 16 | S315T1 | c15t | S531L | M306V | wt | wt | wt | MDR TB | Z Pt Cap Pas Cs Of | 40 | L | - |
| 17 | S315T1 | wt | S531L | M306V | wt | wt | wt | MDR TB | H Rfd Z E | 5 | L | - |
| 18 | S315T1 | wt | S531L | M306V | wt | wt | wt | MDR TB | H R Z E | 27 | IM | - |
| 19 | S315T1 | wt | S531L | wt | wt | wt | wt | MDR TB | Z Pt Cap Pas Cs | 26 | L | - |
| 20 | S315T1 | wt | S531L | M306V | wt | wt | wt | MDR TB | H Z E Rfd | 113 | H | + |
| 21 | wt | wt | wt | wt | wt | wt | wt | TB | Z E Pas Cs Of | 14 | L | - |
| 22 | S315T1 | wt | H526N | wt | wt | wt | wt | MDR TB | Z E Pas Cs K Of | 5 | L | - |
| 23 | S315T1 | t8g | S531L | D354A | wt | wt | c12t | MDR TB | H R Z E | 12 | L | - |
| 24 | S315T1 | wt | S531L | G406A | wt | wt | c12t | MDR TB | Z Pt Cap Pas Cs Lfx | 7 | L | - |
| 25 | S315T1 | wt | S531L | M306V | wt | wt | g10a | MDR TB | Z Pt Cap Pas Lfx | 9 | L | - |
| 26 | S315T1 | wt | S531L | G406A | wt | wt | wt | MDR TB | Z Pt Pas Cs K Lfx | 9 | L | - |
| 27 | S315T1 | wt | S531L | M306V | wt | wt | c14t | MDR TB | E Am Cs Lfx | 6 | L | - |
| 28 | ND | ND | ND | ND | ND | ND | ND | TB | H R Z E | 3 | L | - |
| 29 | wt | wt | wt | wt | wt | wt | wt | TB | H R Z E | 9 | L | - |
| Mtb phenotypes | SP | TB patients | |||
|---|---|---|---|---|---|
| Acid-fastness | Markers | Survival state1 | Growth status2 | ||
| + | + LAM + ESAT-6 – Rv2623 |
solitary | non-replicating | 1 | all the patients and lung TB lesions studied |
| replicating | 2 | 2–4, 6 (cav), 7–10, 17, 18, 20, 22, 23, 24 (tub), 27 (tub) | |||
| in colonies (as irregular clumps) |
non-replicating | 3 | 3–5, 6 (cav), 7–10, 14–19, 22, 23, 24 (tub and dist), 25 (tub and dist), 26, 27–29 (tub and dist) | ||
| replicating | 4 | 4, 6 (cav), 7–10, 16–18, 22, 23, 24 (tub), 27 (tub) | |||
| in colonies with cording morphology |
non-replicating | 5 | 3, 19, 22, 26 | ||
| replicating | 6 | 6 (cav), 7, 8, 10, 18, 24 (tub), 27 (tub) | |||
| re-established2 | replicating | 7 | 4, 6 (cav), 7–10, 13, 14, 18, 20, 23, 24 (tub), 27 (tub) | ||
| – | solitary | ns | 8 | 14–16, 18, 24 (tub), 27 (tub) | |
| – LAM – ESAT-6 + Rv2623 |
solitary | ns | 9 | all the patients and lung TB lesions studied | |
| in colonies (as irregular clumps) |
ns | 10 | 3, 4, 6 (cav), 10, 14–16, 18,19, 22, 23, 24 (tub and dist), 25 (tub and dist), 26, 27–29 (tub and dist) | ||
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).